I don't think so unless GILD is out of control and doesn't mean what they say about strategic fit. Someone replied on my twitter feed regarding GILD acquisition that ACAD is a good fit. Really?
If GILD is really interested in orphan genetic disease, ALXN, VRTX, BMRN would be better fit, but I doubt that's the direction GILD is going. Even BIVV would be better fit for GILD.
News 
Market Data 
Discover 
AI
